Literature DB >> 1452610

Gas chromatographic-mass spectrometric method for routine monitoring of 5-fluorouracil in plasma of patients receiving low-level protracted infusions.

L W Anderson1, R J Parker, J M Collins, J D Ahlgren, D Wilkinson, J M Strong.   

Abstract

A gas chromatographic-mass spectrometric (GC-MS) method is described which quantitates 5-fluorouracil (5-FU) plasma levels ranging from 0.5 to 50 ng/ml. The analysis uses two internal standards, 1,3-[15N2]-5-fluorouracil and 5-chlorouracil. Extraction and derivatization of the pyrimidine bases were accomplished in a single step using acetonitrile. Compounds were analyzed as their 1,3-dipentafluorobenzyl derivatives by electron-impact MS, and the GC-MS analysis was automated with respect to sample injection and data reduction. Stability of the analysis was demonstrated by continuous unattended analysis of 5-FU in human plasma for periods of up to three days with no deterioration of the quantitative results. The method is applicable to quantitating 5-FU plasma levels in patients receiving protracted infusions of the drug for colorectal cancer or other malignancies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1452610     DOI: 10.1016/0378-4347(92)80272-r

Source DB:  PubMed          Journal:  J Chromatogr


  3 in total

1.  Derivatization of 5-fluorouracil with 4-bromomethyl-7-methoxycoumarin for determination by liquid chromatography-mass spectrometry.

Authors:  K Wang; M Nano; T Mulligan; E D Bush; R W Edom
Journal:  J Am Soc Mass Spectrom       Date:  1998-09       Impact factor: 3.109

2.  A Stability-Indicating RP-HPLC Assay Method for 5-Fluorouracil.

Authors:  V R Sinha; R V Kumar; J R Bhinge
Journal:  Indian J Pharm Sci       Date:  2009-11       Impact factor: 0.975

3.  A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

Authors:  Joseph P Eder; Rocio Garcia-Carbonero; Jeffrey W Clark; Jeffrey G Supko; Thomas A Puchalski; David P Ryan; Pamela Deluca; Antoinette Wozniak; Angela Campbell; John Rothermel; Patricia LoRusso
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.